
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/221960/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preoperative neutrophil-to-platelet ratio as a potential prognostic factor for gastric cancer with positive peritoneal lavage cytology in the absence of other non-curative factors: a multi-institutional dataset analysis. Surgery Today, 2023, 53, 198-206.	1.5	2
2	Prognostic impact of a microscopic positive margin in patients undergoing gastrectomy for gastric cancer: a propensity score‑matched analysis of a multi‑institutional dataset. Surgery Today, 2022, 52, 559-566.	1.5	2
3	E-PASS scoring system serves as a predictor of short- and long-term outcomes in gastric cancer surgery. Surgery Today, 2022, 52, 914-922.	1.5	2
4	SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 2699-2709.	1.5	3
5	ASO Visual Abstract: SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 2710.	1.5	0
6	Drain Amylase Concentrations at 3 h After Gastrectomy Enhance Early Prediction of Postoperative Peripancreatic Inflammatory Fluid Collection. World Journal of Surgery, 2022, 46, 648-655.	1.6	0
7	Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 578-585.	1.1	6
8	Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer. Molecular Cancer, 2022, 21, 42.	19.2	43
9	A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study. Molecular Cancer, 2022, 21, 44.	19.2	29
10	Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. Gastric Cancer, 2022, 25, 558-572.	5.3	14
11	Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. Cancer Discovery, 2022, 12, 692-711.	9.4	58
12	ASO Author Reflections: Optimized Cutoff Value of Albumin–Bilirubin Score to Predict Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Radical Resection. Annals of Surgical Oncology, 2022, , 1.	1.5	0
13	Prognostic Value of a Modified Albumin–Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection. Annals of Surgical Oncology, 2022, 29, 4889-4896.	1.5	7
14	Expression of cellular retinoic acid binding protein 1 predicts peritoneal recurrence of gastric cancer. International Journal of Oncology, 2022, 60, .	3.3	4
15	ASO Visual Abstract: Prognostic Value of a Modified Albumin–Bilirubin Grade Designed for Patients with Esophageal Squamous Cell Carcinoma after Radical Resection. Annals of Surgical Oncology, 2022, , 1.	1.5	1
16	Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy. Journal of Gastroenterology, 2022, 57, 640-653.	5.1	2
17	High Serum Uric Acid Levels Could Be a Risk Factor of Hepatocellular Carcinoma Recurrences. Nutrition and Cancer, 2021, 73, 996-1003.	2.0	6
18	Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus. Surgery Today, 2021, 51, 153-158.	1.5	2

MITSURO KANDA

#	Article	IF	CITATIONS
19	Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database. Surgery Today, 2021, 51, 821-828.	1.5	4
20	miR-23b-3p Plays an Oncogenic Role in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 3416-3426.	1.5	11
21	Randomised phase II trial of capecitabine plus oxaliplatinÂwith continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study). European Journal of Cancer, 2021, 144, 61-71.	2.8	3
22	Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 2277-2286.	1.5	11
23	Tissue <i>RNFT2</i> Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer. Anticancer Research, 2021, 41, 609-617.	1.1	5
24	Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Pancreas, 2021, 50, 37-46.	1.1	0
25	Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer. Clinical Cancer Research, 2021, 27, 2292-2300.	7.0	17
26	Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53–Bcl-2 intrinsic apoptosis pathway. British Journal of Cancer, 2021, 124, 1449-1460.	6.4	17
27	G-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer. British Journal of Cancer, 2021, 125, 220-228.	6.4	13
28	Accurate Prediction of Prognosis After Radical Resection of Gastric Cancer by the Modified Systemic Inflammation Score; a Multicenter Dataset Analysis. World Journal of Surgery, 2021, 45, 2513-2520.	1.6	6
29	Efficacy of Splenectomy for Proximal Gastric Cancer with Greater Curvature Invasion or Type 4 Tumor: a Propensity Score Analysis of a Multiâ€Institutional Dataset. World Journal of Surgery, 2021, 45, 2840-2848.	1.6	2
30	Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells. Oncogene, 2021, 40, 5495-5504.	5.9	12
31	Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy. Clinical Epigenetics, 2021, 13, 172.	4.1	1
32	Pancreatic Fat and Body Composition Measurements by Computed Tomography are Associated with Pancreatic Fistula After Pancreatectomy. Annals of Surgical Oncology, 2021, 28, 530-538.	1.5	27
33	Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer. Histology and Histopathology, 2021, 36, 817-832.	0.7	3
34	Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Cancers, 2021, 13, 36.	3.7	12
35	Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer. Current Oncology, 2021, 28, 4080-4092.	2.2	3
36	Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer. Oncology Reports, 2021, 47, .	2.6	9

#	Article	IF	CITATIONS
37	Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial. Journal of Clinical Medicine, 2021, 10, 5666.	2.4	8
38	Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial. Contemporary Clinical Trials Communications, 2021, 24, 100853.	1.1	0
39	Preoperative six-minute walk distance as a predictor of postoperative complication in patients with esophageal cancer. Ecological Management and Restoration, 2020, 33, .	0.4	14
40	Detection of indocyanine green fluorescence to determine tumor location during laparoscopic gastrectomy for gastric cancer: Results of a prospective study. Asian Journal of Endoscopic Surgery, 2020, 13, 160-167.	0.9	15
41	The Preoperative Prognostic Nutritional Index Predicts Short-Term and Long-Term Outcomes of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-Institution Dataset. Digestive Surgery, 2020, 37, 135-144.	1.2	36
42	Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II). International Journal of Clinical Oncology, 2020, 25, 118-125.	2.2	6
43	Preoperative predictors of postoperative complications after gastric cancer resection. Surgery Today, 2020, 50, 3-11.	1.5	48
44	Tumor size  ≥50Âmm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative Sâ€1ÂMonotherapy: Analysis of a Multiâ€institution Dataset. World Journal of Surgery, 2020, 44, 194-201.	1.6	4
45	Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer. International Journal of Cancer, 2020, 146, 2865-2876.	5.1	18
46	Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study. Gastric Cancer, 2020, 23, 203-211.	5.3	29
47	Prognosis After Laparoscopic Gastrectomy in Patients with Pathological Stage II or III Gastric Cancer Who Were Preoperatively Diagnosed with Clinical Stage I: Propensity Score Matching Analysis of a Multicenter Dataset. Annals of Surgical Oncology, 2020, 27, 268-275.	1.5	2
48	Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis. Oncology, 2020, 98, 48-52.	1.9	5
49	Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 2081-2089.	1.5	12
50	PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer. Annals of Surgical Oncology, 2020, 27, 2071-2080.	1.5	13
51	Optimized Cutoff Value of Serum Squamous Cell Carcinoma Antigen Concentration Accurately Predicts Recurrence After Curative Resection of Squamous Cell Carcinoma of the Esophagus. Annals of Surgical Oncology, 2020, 27, 1233-1240.	1.5	14
52	Clinical impact of additional therapy for residual pancreatic cancer. Surgery Today, 2020, 50, 440-448.	1.5	1
53	Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 887-895.	1.5	50
54	ASO Author Reflections: Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Annals of Surgical Oncology, 2020, 27, 3206-3207.	1.5	0

#	Article	IF	CITATIONS
55	STRA6 Expression Serves as a Prognostic Biomarker of Gastric Cancer. Cancer Genomics and Proteomics, 2020, 17, 509-516.	2.0	9
56	Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer. Molecular Cancer, 2020, 19, 131.	19.2	48
57	Accurate Risk Stratification of Patients with Nodeâ€Positive Gastric Cancer by Lymph Node Ratio. World Journal of Surgery, 2020, 44, 4184-4192.	1.6	8
58	AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer. Anticancer Research, 2020, 40, 6713-6721.	1.1	9
59	Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting SYT13 to Treat Peritoneal Metastasis of Gastric Cancer. Molecular Therapy - Nucleic Acids, 2020, 22, 791-802.	5.1	30
60	Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer. Cancer Medicine, 2020, 9, 5392-5399.	2.8	6
61	An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. Oncologist, 2020, 25, e1650-e1654.	3.7	7
62	Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Pancreas, 2020, 49, 699-705.	1.1	8
63	Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma. Cancer Genomics and Proteomics, 2020, 17, 391-400.	2.0	6
64	KCNJ15 Expression and Malignant Behavior of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 2559-2568.	1.5	11
65	Propensity-score-matched analysis of a multi-institutional dataset to compare postoperative complications between Billroth I and Roux-en-Y reconstructions after distal gastrectomy. Gastric Cancer, 2020, 23, 734-745.	5.3	18
66	Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. British Journal of Cancer, 2020, 122, 771-777.	6.4	48
67	Systemic Inflammation Score as a Predictor of Pneumonia after Radical Resection of Gastric Cancer: Analysis of a Multi-Institutional Dataset. Digestive Surgery, 2020, 37, 401-410.	1.2	12
68	ASO Author Reflections: KCNJ15 Expression and Malignant Behavior of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 2569-2570.	1.5	0
69	Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 3247-3256.	1.5	9
70	ASO Author Reflections: Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 3257-3258.	1.5	0
71	Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Annals of Surgical Oncology, 2020, 27, 3195-3205.	1.5	11
72	Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Anticancer Research, 2020, 40, 1843-1853.	1.1	12

#	Article	IF	CITATIONS
73	MZB1 expression indicates poor prognosis in estrogen receptor‑positive breast cancer. Oncology Letters, 2020, 20, 1-1.	1.8	14
74	Association between Lymphovascular Invasion and Recurrence in Patients with pT1N+ or pT2–3N0 Gastric Cancer: a Multi-institutional Dataset Analysis. Journal of Gastric Cancer, 2020, 20, 41.	2.5	9
75	Is the measurement of drain amylase content useful for predicting pancreas-related complications after gastrectomy with systematic lymphadenectomy?. World Journal of Gastroenterology, 2020, 26, 1594-1600.	3.3	7
76	D2 lymph node dissection confers little benefit on the overall survival of older patients with resectable gastric cancer: a propensity score-matching analysis of a multi-institutional dataset. Surgery Today, 2020, 50, 1434-1442.	1.5	9
77	Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2281-2285.	1.2	4
78	A prospective trial to evaluate treatment effects of a β-hydroxy-β-methylbutyrate containing nutrient for leakage at the anastomotic site after esophagectomy. Nagoya Journal of Medical Science, 2020, 82, 33-37.	0.3	0
79	Incorporating molecular biomarkers into clinical practice for gastric cancer. Expert Review of Anticancer Therapy, 2019, 19, 757-771.	2.4	11
80	Multiâ€institutional analysis of the prognostic significance of postoperative complications after curative resection for gastric cancer. Cancer Medicine, 2019, 8, 5194-5201.	2.8	32
81	Recent advances in molecular biomarkers for patients with hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 725-738.	3.1	15
82	Comparison of nonâ€invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma. Hepatology Research, 2019, 49, 1305-1315.	3.4	12
83	Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis. BMC Surgery, 2019, 19, 143.	1.3	24
84	Modified Systemic Inflammation Score is Useful for Risk Stratification After Radical Resection of Squamous Cell Carcinoma of the Esophagus. Annals of Surgical Oncology, 2019, 26, 4773-4781.	1.5	19
85	Establishment of Peritoneal and Hepatic Metastasis Mouse Xenograft Models Using Gastric Cancer Cell Lines. In Vivo, 2019, 33, 1785-1792.	1.3	18
86	<i>PRAME</i> Expression as a Potential Biomarker for Hematogenous Recurrence of Esophageal Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 5943-5951.	1.1	9
87	Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer. Anticancer Research, 2019, 39, 5903-5910.	1.1	9
88	Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer. Anticancer Research, 2019, 39, 6125-6133.	1.1	15
89	Expression, Function, and Prognostic Value of MAGE-D4 Protein in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 6015-6023.	1.1	5
90	Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival. Annals of Surgical Oncology, 2019, 26, 1535-1543.	1.5	16

#	Article	IF	CITATIONS
91	Risk Prediction of Postoperative Pneumonia After Subtotal Esophagectomy Based on Preoperative Serum Cholinesterase Concentrations. Annals of Surgical Oncology, 2019, 26, 3718-3726.	1.5	27
92	The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer. Gastric Cancer, 2019, 22, 1143-1152.	5.3	31
93	ASO Author Reflections: Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival. Annals of Surgical Oncology, 2019, 26, 596-597.	1.5	1
94	ASO Author Reflections: Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer. Annals of Surgical Oncology, 2019, 26, 592-593.	1.5	0
95	Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. Hpb, 2019, 21, 1211-1218.	0.3	19
96	Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset. Gastric Cancer, 2019, 22, 1215-1225.	5.3	39
97	Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of Sâ€1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multiâ€Institutional Dataset Analysis. World Journal of Surgery, 2019, 43, 2016-2024.	1.6	6
98	The Controlling Nutritional Status Score Serves as a Predictor of Short- and Long-Term Outcomes for Patients with Stage 2 or 3 Gastric Cancer: Analysis of a Multi-institutional Data Set. Annals of Surgical Oncology, 2019, 26, 456-464.	1.5	61
99	Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer. Annals of Surgical Oncology, 2019, 26, 836-844.	1.5	22
100	Intraoperative Blood Loss is Associated with Shortened Postoperative Survival of Patients with Stage II/III Gastric Cancer: Analysis of a Multiâ€institutional Dataset. World Journal of Surgery, 2019, 43, 870-877.	1.6	32
101	Long-term quality of life and nutrition status of the aboral pouch reconstruction after total gastrectomy for gastric cancer: a prospective multicenter observational study (CCOG1505). Gastric Cancer, 2019, 22, 607-616.	5.3	21
102	Perioperative and prognostic implication of albuminâ€bilirubinâ€ <scp>TNM</scp> score in Childâ€Pugh class A hepatocellular carcinoma. Annals of Gastroenterological Surgery, 2019, 3, 65-74.	2.4	12
103	Number of retrieved lymph nodes is an independent prognostic factor after total gastrectomy for patients with stage III gastric cancer: propensity score matching analysis of a multi-institution dataset. Gastric Cancer, 2019, 22, 853-863.	5.3	32
104	Optical trocar access for initial trocar placement in laparoscopic gastrointestinal surgery: <scp>A</scp> propensity scoreâ€matching analysis. Asian Journal of Endoscopic Surgery, 2019, 12, 37-42.	0.9	7
105	Long-lasting discussion: Adverse effects of intraoperative blood loss and allogeneic transfusion on prognosis of patients with gastric cancer. World Journal of Gastroenterology, 2019, 25, 2743-2751.	3.3	38
106	Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 17-27.	2.0	22
107	Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy. Journal of Gastric Cancer, 2019, 19, 183.	2.5	12
108	A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. Cancer Chemotherapy and Pharmacology, 2018, 81, 829-838.	2.3	4

#	Article	IF	CITATIONS
109	Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2083-2090.	1.5	32
110	A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial. Gastric Cancer, 2018, 21, 1014-1023.	5.3	34
111	Significance of Preoperative Systemic Inflammation Score in Shortâ€Term and Longâ€Term Outcomes of Patients with Pathological T2–4 Gastric Cancer After Radical Gastrectomy. World Journal of Surgery, 2018, 42, 3277-3285.	1.6	29
112	Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials. Diseases of the Colon and Rectum, 2018, 61, 461-471.	1.3	12
113	Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer. Annals of Surgery, 2018, 267, 495-503.	4.2	81
114	Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy. Digestive Surgery, 2018, 35, 55-63.	1.2	28
115	Nutritional Recovery after Open and Laparoscopic Distal Gastrectomy for Early Gastric Cancer: A Prospective Multicenter Comparative Trial (CCOG1204). Digestive Surgery, 2018, 35, 11-18.	1.2	7
116	Preoperative Albumin–Bilirubin Grade Predicts Recurrences After Radical Gastrectomy in Patients with pT2â€4 Gastric Cancer. World Journal of Surgery, 2018, 42, 773-781.	1.6	40
117	Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multiâ€institutional dataset. Cancer Medicine, 2018, 7, 6020-6029.	2.8	14
118	Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Pancreas, 2018, 47, 1350-1356.	1.1	8
119	RASEF expression correlates with hormone receptor status in breast cancer. Oncology Letters, 2018, 16, 7223-7230.	1.8	3
120	Copineïį½5 expression predicts prognosis following curative resection of esophageal squamous cell carcinoma. Oncology Reports, 2018, 40, 3772-3780.	2.6	11
121	ASO Author Reflections: Troponin I2—A Specific Biomarker for Detection and Prediction of Peritoneal Metastasis in Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 709-710.	1.5	10
122	Cutting-edge evidence of adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1109-1122.	3.0	3
123	Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 124-136.	2.0	18
124	Expression of sushi domain containing two reflects the malignant potential of gastric cancer. Cancer Medicine, 2018, 7, 5194-5204.	2.8	19
125	Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Pancreas, 2018, 47, 974-979.	1.1	23
126	Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. Pancreas, 2018, 47, 823-829.	1.1	36

#	Article	IF	CITATIONS
127	Pattern-Specific Transcriptomics Identifies <i>ASGR2</i> as a Predictor of Hematogenous Recurrence of Gastric Cancer. Molecular Cancer Research, 2018, 16, 1420-1429.	3.4	12
128	SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells. Oncogene, 2018, 37, 5355-5366.	5.9	55
129	Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Scientific Reports, 2018, 8, 9846.	3.3	29
130	Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer. British Journal of Surgery, 2018, 105, 1349-1358.	0.3	44
131	A novel dualâ€marker expression panel for easy and accurate risk stratification of patients with gastric cancer. Cancer Medicine, 2018, 7, 2463-2471.	2.8	10
132	Review of recent efforts to discover biomarkers for early detection, monitoring, prognosis, and prediction of treatment responses of patients with gastric cancer. Expert Review of Gastroenterology and Hepatology, 2018, 12, 657-670.	3.0	38
133	Review of recent molecular landscape knowledge of gastric cancer. Histology and Histopathology, 2018, 33, 11-26.	0.7	38
134	Emerging evidence of molecular biomarkers in hepatocellular carcinoma. Histology and Histopathology, 2018, 33, 343-355.	0.7	14
135	Integrated multigene expression panel to prognosticate patients with gastric cancer. Oncotarget, 2018, 9, 18775-18785.	1.8	8
136	<editors' choice=""> Efficacy of enteral nutrients containing β-hydroxy-β-methylbutyrate, glutamine, and arginine for the patients with anastomotic leakage after gastrectomy: study protocol of a multicenter phase II clinical trial. Nagoya Journal of Medical Science, 2018, 80, 351-355.</editors'>	0.3	3
137	Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. Journal of Gastroenterology, 2017, 52, 81-93.	5.1	51
138	The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. International Journal of Oncology, 2017, 50, 381-386.	3.3	26
139	Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. International Journal of Surgery, 2017, 39, 45-51.	2.7	74
140	Intraperitoneal Administration of Plasma-Activated Medium: Proposal of a Novel Treatment Option for Peritoneal Metastasis From Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 1188-1194.	1.5	74
141	Stapling an extracorporeal Billrothâ€l anastomosis by the complete double stapling technique after laparoscopyâ€assisted distal gastrectomy. Asian Journal of Endoscopic Surgery, 2017, 10, 137-142.	0.9	1
142	GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer. Scientific Reports, 2017, 7, 42089.	3.3	24
143	Expression of regulatory factor X1 can predict the prognosis of breast cancer. Oncology Letters, 2017, 13, 4334-4340.	1.8	6
144	The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). BMC Cancer, 2017, 17, 243.	2.6	13

#	Article	IF	CITATIONS
145	Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Surgery, 2017, 162, 784-791.	1.9	27
146	Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003). International Journal of Clinical Oncology, 2017, 22, 1052-1059.	2.2	5
147	Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2–4 gastric cancer. Gastric Cancer, 2017, 20, 736-743.	5.3	19
148	FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 3438-3445.	1.5	39
149	Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 502-509.	1.5	46
150	The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Annals of Surgical Oncology, 2017, 24, 546-553.	1.5	7
151	Identification of NCCRP1 as an epigenetically regulated tumor suppressor and biomarker for malignant phenotypes of squamous cell carcinoma of the esophagus. Oncology Letters, 2017, 14, 4822-4828.	1.8	15
152	Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer, 2017, 17, 610.	2.6	15
153	FBXO50 Enhances the Malignant Behavior of Gastric Cancer Cells. Annals of Surgical Oncology, 2017, 24, 3771-3779.	1.5	19
154	Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells. Oncology Reports, 2017, 38, 1760-1766.	2.6	25
155	An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 71070-71079.	1.8	4
156	Association of Inflammasome Components in Background Liver with Poor Prognosis After Curatively-resected Hepatocellular Carcinoma. Anticancer Research, 2017, 37, 293-300.	1.1	18
157	Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer. World Journal of Gastroenterology, 2017, 23, 2519.	3.3	43
158	Molecular mechanisms of peritoneal dissemination in gastric cancer. World Journal of Gastroenterology, 2016, 22, 6829.	3.3	121
159	Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus. Ecological Management and Restoration, 2016, 29, 663-669.	0.4	3
160	S-1 plus <i>nab</i> -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Journal of Surgical Oncology, 2016, 113, 413-419.	1.7	14
161	Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy. Ecological Management and Restoration, 2016, 29, 598-602.	0.4	14
162	Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncology Letters, 2016, 12, 3662-3668.	1.8	14

#	Article	IF	CITATIONS
163	Modified twoâ€dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. Cancer Science, 2016, 107, 1492-1498.	3.9	5
164	Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine (United States), 2016, 95, e3781.	1.0	105
165	Prognostic relevance of SAMSN1 expression in gastric cancer. Oncology Letters, 2016, 12, 4708-4716.	1.8	16
166	Preoperative Identification of a Prognostic Factor for Pancreatic Neuroendocrine Tumors Using Multiphase Contrast-Enhanced Computed Tomography. Pancreas, 2016, 45, 198-203.	1.1	27
167	NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncology Letters, 2016, 11, 1847-1854.	1.8	26
168	Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Langenbeck's Archives of Surgery, 2016, 401, 1143-1152.	1.9	28
169	Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection. International Journal of Surgery, 2016, 30, 136-142.	2.7	54
170	Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is Associated with Malignant Phenotype of Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 532-539.	1.5	17
171	Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. International Journal of Cancer, 2016, 139, 2290-2298.	5.1	39
172	Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. International Journal of Oncology, 2016, 49, 1195-1202.	3.3	40
173	Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer. Medicine (United) Tj ETQq1 1	0.784314 1.0	rgBT/Overloo
174	Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemotherapy and Pharmacology, 2016, 78, 1253-1261.	2.3	11
175	The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity. Medicine (United States), 2016, 95, e4282.	1.0	28
176	Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue. Oncology Letters, 2016, 12, 4821-4828.	1.8	17
177	Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 4353-4362.	2.4	20
178	A resected case of symptomatic acinar cell cystadenoma of the pancreas displacing the main pancreatic duct. Surgical Case Reports, 2016, 2, 39.	0.6	12
179	Function and diagnostic value of <scp>Anosminâ€l </scp> in gastric cancer progression. International Journal of Cancer, 2016, 138, 721-730.	5.1	55
180	Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer, 2016, 19, 255-263.	5.3	70

#	Article	IF	CITATIONS
181	Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 1934-1940.	1.5	38
182	Adverse Effects of Intraoperative Blood Loss on Long-Term Outcomes after Curative Gastrectomy of Patients with Stage II/III Gastric Cancer. Digestive Surgery, 2016, 33, 121-128.	1.2	43
183	Modified Blumgart Suturing Technique for Remnant Closure After Distal Pancreatectomy: a Propensity Score-Matched Analysis. Journal of Gastrointestinal Surgery, 2016, 20, 374-384.	1.7	17
184	Comparison of the international consensus guidelines for predicting malignancy in intraductal papillary mucinous neoplasms. Surgery, 2016, 159, 878-884.	1.9	53
185	The Prognostic Relevance of Subcarinal Lymph Node Dissection in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2016, 23, 611-618.	1.5	19
186	Combination of continuous paravertebral block and epidural anesthesia in postoperative pain control after esophagectomy. Esophagus, 2016, 13, 42-47.	1.9	10
187	The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression. Annals of Surgical Oncology, 2016, 23, 214-221.	1.5	41
188	Metastatic pathway-specific transcriptome analysis identifies <i>MFSD4</i> as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget, 2016, 7, 13667-13679.	1.8	46
189	Overexpression of <i>ankyrin1</i> promotes pancreatic cancer cell growth. Oncotarget, 2016, 7, 34977-34987.	1.8	18
190	Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma. Anticancer Research, 2016, 36, 4639-4646.	1.1	7
191	Clinical features of colorectal mucinous and poorly differentiated adenocarcinomas; study concept of a propensity score analysis in a pooled data of 5530 patients. Annals of Cancer Research and Therapy, 2016, 24, 52-53.	0.3	1
192	Short-term outcomes after conventional transthoracic esophagectomy. Nagoya Journal of Medical Science, 2016, 78, 69-78.	0.3	10
193	Excess Weight Adversely Influences Treatment Length of Postoperative Pancreatic Fistula. Pancreas, 2015, 44, 971-976.	1.1	24
194	Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75Âyears of age with metastatic colorectal cancer. BMC Cancer, 2015, 15, 786.	2.6	13
195	<i>CD44</i> single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. Journal of Surgical Oncology, 2015, 112, 622-628.	1.7	14
196	SMAD4 Expression Predicts Local Spread and Treatment Failure in Resected Pancreatic Cancer. Pancreas, 2015, 44, 660-664.	1.1	57
197	A Vascular Endothelial Growth Factor Gene Polymorphism Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasm. Pancreas, 2015, 44, 608-614.	1.1	2
198	Factors related to occurrence and aggravation of pancreatic fistula after radical gastrectomy for gastric cancer. Journal of Surgical Oncology, 2015, 112, 381-386.	1.7	23

#	Article	IF	CITATIONS
199	Oral Food Intake Versus Fasting on Postoperative Pancreatic Fistula After Distal Pancreatectomy. Medicine (United States), 2015, 94, e2398.	1.0	15
200	Recent advances in the molecular diagnostics of gastric cancer. World Journal of Gastroenterology, 2015, 21, 9838.	3.3	92
201	Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment. Medicine (United States), 2015, 94, e1647.	1.0	55
202	Effectiveness of plasma treatment on pancreatic cancer cells. International Journal of Oncology, 2015, 47, 1655-1662.	3.3	98
203	Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 2546-2554.	3.3	11
204	Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus. International Journal of Oncology, 2015, 47, 1811-1818.	3.3	24
205	Significance of the Splenic Vein and Its Branches in Pancreatoduodenectomy with Resection of the Portal Vein System. Digestive Surgery, 2015, 32, 382-388.	1.2	26
206	B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 641-648.	3.3	39
207	CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 1963-1970.	3.3	14
208	High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis. Oncology Reports, 2015, 33, 767-773.	2.6	8
209	Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. Journal of Gastroenterology, 2015, 50, 590-600.	5.1	31
210	Method of Bilateral Pleural Drainage by Single Blake Drain After Esophagectomy. World Journal of Surgery, 2015, 39, 727-731.	1.6	5
211	Diversity of Clinical Implication of B-Cell Translocation Gene 1 Expression by Histopathologic and Anatomic Subtypes of Gastric Cancer. Digestive Diseases and Sciences, 2015, 60, 1256-1264.	2.3	40
212	Protein tyrosine kinase 7: a hepatocellular carcinoma-related gene detected by triple-combination array. Journal of Surgical Research, 2015, 195, 444-453.	1.6	10
213	Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Annals of Surgical Oncology, 2015, 22, 1499-1507.	1.5	25
214	Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncology Letters, 2015, 9, 1201-1206.	1.8	18
215	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. Clinical Gastroenterology and Hepatology, 2015, 13, 963-969.e4.	4.4	74
216	Vein resections >3Âcm during pancreatectomy are associated withÂpoor 1-year patency rates. Surgery, 2015, 157, 708-715.	1.9	51

#	Article	IF	CITATIONS
217	Influence of Food Intake on the Healing Process of Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Multi-institutional Randomized Controlled Trial. Annals of Surgical Oncology, 2015, 22, 3905-3912.	1.5	34
218	Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2015, 22, 1453-1460.	1.5	17
219	Serosal Invasion Strongly Associated With Recurrence After Curative Hepatic Resection of Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e602.	1.0	11
220	Preoperative Internal Biliary Drainage Increases the Risk of Bile Juice Infection and Pancreatic Fistula After Pancreatoduodenectomy. Pancreas, 2015, 44, 465-470.	1.1	58
221	Feeding Duodenostomy Decreases the Incidence of Mechanical Obstruction After Radical Esophageal Cancer Surgery. World Journal of Surgery, 2015, 39, 1105-1110.	1.6	22
222	Updated evidence on adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1549-1560.	3.0	47
223	Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis. Surgery, 2015, 158, 1573-1580.	1.9	53
224	Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Ecological Management and Restoration, 2015, 28, 188-195.	0.4	15
225	Effectiveness of plasma treatment on gastric cancer cells. Gastric Cancer, 2015, 18, 635-643.	5.3	83
226	Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer, 2015, 18, 288-296.	5.3	45
227	Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 10584.	3.3	66
228	Intraductal Papillary Mucinous Carcinoma with Portal Annular Pancreas Anomaly Treated by Middle-preserving Pancreatectomy. Japanese Journal of Gastroenterological Surgery, 2015, 48, 706-714.	0.1	2
229	Abstract 3423: Expression level of inflammasomes compornents NLRP3, NLRC4, and CASP1 in background non tumorous tissue were associated with worse prognosis for curatively resected hepatocellular carcinoma. , 2015, , .		0
230	Abstract 4101: Clinical significance of ZEB1 mRNA levels in peritoneal washing for gastric cancer. , 2015, , .		0
231	Abstract 3422: Alteration of aldo-keto reductase family 1, member B10 (AKR1B10) expression among tumor and background non-tumorous tissue of curatively resected hepatocellular carcinoma is associated with worse prognosis. , 2015, , .		0
232	Abstract 4253: A vascular endothelial growth factor gene polymorphism predicts malignant potential in intraductal papillary mucinous neoplasm. , 2015, , .		0
233	Estimated pancreatic parenchymal remnant volume accurately predicts clinically relevant pancreatic fistula after pancreatoduodenectomy. Surgery, 2014, 156, 601-610.	1.9	38
234	Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 88.	8.6	27

#	Article	IF	CITATIONS
235	Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. Clinical and Translational Gastroenterology, 2014, 5, e62.	2.5	28
236	Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncology Reports, 2014, 31, 693-700.	2.6	24
237	Clinical significance of expression and epigenetic profiling of <i>TUSC1</i> in gastric cancer. Journal of Surgical Oncology, 2014, 110, 136-144.	1.7	30
238	Comparison of inflammationâ€based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 682-688.	2.6	72
239	Identification of the collagen type 1 alpha 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer, 2014, 14, 108.	2.6	71
240	The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 847-855.	2.3	45
241	Clinical Implication of Morphological Subtypes in Management of Intraductal Papillary Mucinous Neoplasm. Annals of Surgical Oncology, 2014, 21, 2444-2452.	1.5	41
242	Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10. Annals of Surgical Oncology, 2014, 21, 691-698.	1.5	23
243	Preservation of the Pyloric Ring Confers Little Benefit in Patients Undergoing Total Pancreatectomy. World Journal of Surgery, 2014, 38, 1807-1813.	1.6	8
244	Modified Blumgart Anastomosis for Pancreaticojejunostomy: Technical Improvement in Matched Historical Control Study. Journal of Gastrointestinal Surgery, 2014, 18, 1108-1115.	1.7	145
245	Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma. Journal of Surgical Oncology, 2014, 110, 764-769.	1.7	51
246	Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer. Journal of Surgical Oncology, 2014, 110, 745-751.	1.7	42
247	Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 66.	8.6	49
248	The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surgery Today, 2014, 44, 1692-1701.	1.5	41
249	Expression Analysis of THOP1 in Background Liver, a Prognostic Predictive Factor in Hepatocellular Carcinoma, Extracted by Multiarray Analysis. Annals of Surgical Oncology, 2014, 21, 443-450.	1.5	20
250	Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncology Reports, 2014, 31, 1305-1313.	2.6	19
251	Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. International Journal of Oncology, 2014, 44, 44-52.	3.3	41
252	Hepatectomy for hepatocellular carcinoma in patients with hemophilia. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 824-828.	2.6	12

#	Article	IF	CITATIONS
253	Pancreatoduodenectomy With Portal Vein Resection Is Feasible and Potentially Beneficial for Elderly Patients With Pancreatic Cancer. Pancreas, 2014, 43, 951-958.	1.1	25
254	Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. International Journal of Oncology, 2014, 45, 2005-2012.	3.3	17
255	Neoadjuvant chemoradiotherapy with S-1 in patients with borderline resectable pancreatic cancer Journal of Clinical Oncology, 2014, 32, 302-302.	1.6	5
256	Novel diagnostics for aggravating pancreatic fistulas at the acute phase after pancreatectomy. World Journal of Gastroenterology, 2014, 20, 8535.	3.3	41
257	Overexpression of melanoma-associated antigen D4 as an independent prognostic factor in squamous cell carcinoma of the esophagus Journal of Clinical Oncology, 2014, 32, 71-71.	1.6	0
258	Risk factors that affect continuation of S-1 chemotherapy as an adjuvant setting after radical gastrectomy for gastric cancer Journal of Clinical Oncology, 2014, 32, 151-151.	1.6	0
259	Response to the first-line FOLFOX plus bevacizumab (BEV) therapy to predict responses to the subsequent therapies and survival in the BEV beyond progression (BBP) strategy for metastatic colorectal cancer: A retrospective analysis of CCOG-0801 study Journal of Clinical Oncology, 2014, 32, 428-428.	1.6	0
260	Reduced expression of DENND2D through promoter hypermethylation as an adverse prognostic factor in squamous cell carcinoma of the esophagus Journal of Clinical Oncology, 2014, 32, 58-58.	1.6	0
261	The impact of dose reduction and time delay in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer Journal of Clinical Oncology, 2014, 32, 631-631.	1.6	Ο
262	Abstract 3831: Clinical significance of SMAD4 expression in resectable pancreatic cancer: correlation with tumor progression and recurrence pattern. , 2014, , .		1
263	Abstract 2870: ZGPAT gene expression in non-tumor hepatocellular carcinoma tissue is a likely biomarker for survival risk. , 2014, , .		0
264	Abstract 3822: Correlation between worse prognosis and lower expression of theTPPPgene in patients with hepatocellular carcinoma, detected by multiarray analysis. , 2014, , .		0
265	Abstract 4717: Detection of the Cyclin J (CCNJ) as a new cancer-related gene in human hepatocellular carcinoma by using a method of triple combination array analysis. , 2014, , .		0
266	Abstract 3816: Correlation between worse prognosis and higher expression of theJAK2gene in corresponding non-neoplastic tissue in patients with hepatocellular carcinoma, extracted by multiarray analysis. , 2014, , .		0
267	Abstract 1148: Epithelial to mesenchymal transition might be induced via CD44 isoform switch in colorectal cancer. , 2014, , .		1
268	Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Hepato-Gastroenterology, 2014, 61, 1756-61.	0.5	24
269	Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. Journal of Experimental and Clinical Cancer Research, 2013, 32, 65.	8.6	16
270	Evaluation of MAGEâ€Ð4 expression in hepatocellular carcinoma in Japanese patients. Journal of Surgical Oncology, 2013, 108, 557-562.	1.7	22

#	Article	IF	CITATIONS
271	Mutant TP53 in Duodenal Samples of Pancreatic Juice From Patients With Pancreatic Cancer or High-Grade Dysplasia. Clinical Gastroenterology and Hepatology, 2013, 11, 719-730.e5.	4.4	154
272	Mutant <i>GNAS</i> detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut, 2013, 62, 1024-1033.	12.1	160
273	Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. International Journal of Oncology, 2013, 43, 88-94.	3.3	81
274	A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. OncoTargets and Therapy, 2013, 6, 1805.	2.0	18
275	Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. OncoTargets and Therapy, 2013, 6, 1417.	2.0	32
276	Abstract 3539: A study ofTHOP1, a predictive factor of prognosis in HCC, by multi-array analysis of background liver , 2013, , .		0
277	Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 4303-4312.	7.0	43
278	Preservation of the Pyloric Ring Has Little Value in Surgery for Pancreatic Head Cancer: A Comparative Study Comparing Three Surgical Procedures. Annals of Surgical Oncology, 2012, 19, 176-183.	1.5	58
279	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology, 2012, 142, 730-733.e9.	1.3	568
280	Prognostic Implications of Intraoperative Radiotherapy for Unresectable Pancreatic Cancer. Pancreatology, 2011, 11, 68-75.	1.1	10
281	Pattern of Lymph Node Metastasis Spread in Pancreatic Cancer. Pancreas, 2011, 40, 951-955.	1.1	89
282	Comparison of Pancreatic Head Resection With Segmental Duodenectomy and Pylorus-Preserving Pancreatoduodenectomy for Benign and Low-Grade Malignant Neoplasms of the Pancreatic Head. Pancreas, 2011, 40, 1258-1263.	1.1	28
283	Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas. Pancreas, 2011, 40, 1029-1033.	1.1	35
284	Impact of Operative Blood Loss on Survival in Invasive Ductal Adenocarcinoma of the Pancreas. Pancreas, 2011, 40, 3-9.	1.1	63
285	Reduced Expression of Reelin (RELN) Gene Is Associated With High Recurrence Rate of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2011, 18, 572-579.	1.5	49
286	Recurrence Pattern and Prognosis of Pancreatic Cancer After Pancreatic Fistula. Annals of Surgical Oncology, 2011, 18, 2329-2337.	1.5	56
287	Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Molecular Carcinogenesis, 2011, 50, 571-579.	2.7	86
288	Operative Treatment of Thrombotic Occlusion of the Portal Vein Immediately After Pancreatectomy With Portal Vein Resection. Pancreas, 2010, 39, 265-266.	1.1	9

#	Article	IF	CITATIONS
289	Invasion of the Splenic Artery Is a Crucial Prognostic Factor in Carcinoma of the Body and Tail of the Pancreas. Annals of Surgery, 2010, 251, 483-487.	4.2	65
290	Operative Treatment of Pancreatic Ductal Adenocarcinoma With Extensive Portal Venous Tumor Embolism. Pancreas, 2010, 39, 268-269.	1.1	1
291	Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1, EFEMP1, a Novel Tumor-Suppressor Gene Detected in Hepatocellular Carcinoma Using Double Combination Array Analysis. Annals of Surgical Oncology, 2010, 17, 923-932.	1.5	69
292	Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery, 2010, 148, 285-290.	1.9	71
293	Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Letters, 2010, 289, 170-177.	7.2	49
294	Abstract 1733: Fibulin 1 is a novel tumor suppressor gene detected in hepatocellular carcinoma using a double combination array analysis. , 2010, , .		0
295	Abstract 4660: Double combination array analysis detected A kinase anchor protein 12 (AKAP12) gene as a new tumor suppressor gene of hepatocellular carcinoma. , 2010, , .		Ο
296	Abstract 1750: Reduced xpression of Reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. , 2010, , .		0
297	Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. International Journal of Oncology, 2009, 35, 477-83.	3.3	53
298	Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinicoâ€pathological parameters. Journal of Surgical Oncology, 2008, 98, 190-196.	1.7	59